CA3037328C — Tofacitinib oral sustained release dosage forms
Assigned to Pfizer Inc · Expires 2023-01-24 · 3y expired
What this patent protects
The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics. More particularly, there is provided a once daily pharmaceutical dosa…
USPTO Abstract
The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics. More particularly, there is provided a once daily pharmaceutical dosage form comprising a core comprising 22 mg of tofacitinib, or an equivalent amount of tofacitinib in the form of a pharmaceutically acceptable salt thereof, and an osmagen, and a semi-permeable membrane coating surrounding the core wherein said coating comprises a water-insoluble polymer.
Drugs covered by this patent
- Xeljanz (Tofacitinib Citrate) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.